Shigellosis in Nepal: 13 years review of nationwide surveillance by Geeta Shakya et al.
RESEARCH ARTICLE Open Access
Shigellosis in Nepal: 13 years review of
nationwide surveillance
Geeta Shakya, Jyoti Acharya, Shailaja Adhikari and Nisha Rijal*
Abstract
Background: Shigella is a major cause of gastroenteritis especially in children. In developing countries, the incidence is
frequent and results are often life threatening. Changing epidemiology and emerging antibiotic resistance warrants
continuous monitoring of susceptibility. The present study highlights the changing epidemiology and drug resistance
patterns of Shigella isolated at different hospitals of Nepal over a period of 13 years (Jan. 2003–Dec. 2015).
Methods: This study was carried out in 12 participating laboratories. Stool specimens received at respective
laboratories were processed for isolation and identification of Shigella species and confirmed by serotyping at National
Public Health Laboratory. Antimicrobial resistance patterns were determined by Kirby Baeur disc diffusion test.
Results: A total of 332 isolates were identified as Shigella species of which Shigella flexneri (50 %) was the predominant
serotype. Shigella dysenteriae, Shigella sonnei, Shigella boydii, and untypable Shigella spp. respectively, accounted for 28.6,
27.54, 10.2, 4.5, and 6.6 % of the total number. Change in prevalent serotype is noted over the years. S. dysenteriae was
the prevalent species in Nepal in 2003 and 2004, but since 2005, S. flexneri remained prevalent. Majority of the isolates
were recovered from children aged 1–10 years and was statistically significant (p = 0.023) compared to the other age
groups. High resistance among all Shigella species to the first-line drugs like ampicillin (88 %), cotrimoxazole (76 %),
ciprofloxacin (39 %,) and nalidixic acid (80 %) was observed; 46.1 % of total isolates were multidrug resistant (MDR), and
the most common MDR profile was ampicillin, nalidixic acid, and co-trimoxazole. Prevalence of MDR increased
significantly in 2010 as compared to 2003. Only few Shigella isolates were resistant to ceftriaxone.
Conclusions: The study revealed S. flexneri as the predominant serogroup in Nepal. Children below 10 years were
more prone to the disease. Nalidixic acid, ampicillin, co-trimoxazole, and ciprofloxacin should not be used empirically
as the first-line drugs in treatment of shigellosis. Since the distribution of different species of Shigella and their
antibiotic susceptibility profile may vary from one geographical location to another and may also change with
time, continuous local monitoring of resistance patterns is necessary for appropriate antimicrobial therapy.
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Background
Shigella is one of the most important etiological agents
of diarrhea, in particular, dysentery commonly known as
bacillary dysentery. It is a more severe form than gastro-
enteritis and is responsible for childhood morbidity and
mortality, especially in developing countries [1–4]. In-
gestion of even 100 microorganisms leads after 4–7 days
to an acute diarrhea. Because of delay in humoral re-
sponses, complication and mortality rate due to shigellosis
in children is higher than in other age groups [5]. A litera-
ture review concluded that of the estimated 165 million
cases of Shigella diarrhea that occur annually in the world,
99 % occur in the developing world and the remaining
1 % occurs in industrialized countries. In developing
countries, 69 % of these episodes occur in children under
5 years of age. Moreover, of the 1.1 million deaths attrib-
uted to Shigella infections in developing countries, 60 %
occur in the under 5 age group in children [6].
The genus Shigella comprise of four different species
which are referred to by a letter designation based on
their serological antigen: serotype A-Shigella dysenteriae,
Serotype B-Shigella flexneri, Serotype C-Shigella boydii
and Serotype D-Shigella sonnei. The first three are
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common in developing countries while S. sonnei is com-
mon in developed countries and Iran [7].
Shifts in the prevalent serogroups have been observed
in many parts of the world and so is true for Nepal. Stud-
ies conducted during1999–2002 shows high incidence of
S. dysentriae infection in Nepal [8]. Studies conducted
after 2002 showed prevalence of S. flexneri strains among
Shigella isolates from all parts of Nepal [9–12].
According to WHO report, antimicrobial resistance
pattern for Shigella varies in different parts of the world
and with the time. Over the past decades, Shigella spe-
cies have become progressively resistant to most widely
used antimicrobials [13, 14]. Since the late 1990s, the
fluoroquinolones, including ciprofloxacin, norfloxacin,
and ofloxacin, have been the drug of choice for multidrug-
resistant Shigella infections. However, strains resistant to
the first-line drugs commonly used in the treatment of
shigellosis like ampicillin, cotrimoxazole, and nalidixic and
even ciprofloxacin and norfloxacin has also been reported
from various studies in Nepal and worldwide [9–12, 15].
Ceftriaxone has been used as a reserved antibiotic for
treatment of multidrug-resistant (MDR) Shigella infection
[16]. However, some studies have also reported emerging
ceftriaxone resistance in Shigella. This increasing level
of antimicrobial resistance in Shigella have limited the
therapeutic options and complicated the treatment of
shigellosis.
The purpose of the present study is to determine the
trend of change in Shigella species and their antimicro-




Nepal is divided into five development regions. The study
was carried out in 12 participating laboratories that are
under Antimicrobial Resistance Surveillance network. The
study was conducted in three development regions: central,
eastern, and western development regions and covered six
districts. In the central development region, there were five
surveillance sites in Kathmandu district (National Public
Health Laboratory (NPHL), Bir Hospital, Sukraraj Tropical
Hospital, Kanti Children Hospital, Teaching Hospital) and
two in Lalitpur district (Patan Hospital and KIST hospital).
In the western development region, Western Regional
Hospital and Manipal Teaching Hospital fall in Kaski dis-
trict whereas Lumbini Zonal Hospital falls in Rupandehi
district and United Mission Hospital falls in Palpa district.
Fig. 1 Map of Nepal showing location of participating laboratories in various development regions
Shakya et al. Journal of Health, Population and Nutrition  (2016) 35:36 Page 2 of 9
Only one site BPKIHS falls in Morang district of the east-
ern development region (Fig. 1).
Selection of surveillance sites
Surveillance sites were selected preferring large private/
government hospital laboratories from various development
regions where the diagnostic facilities were adequate and
the probability of patient inflow during outbreaks was
higher.
Sample population and data collection
Diarrheal samples were collected from individual patients
referring to the private or governmental laboratories. A
questionnaire for each subject was filled at respective la-
boratories mentioning basic details of the patient, age
(months), sex, location of residence, and travel. A history
from all patients was also recorded, including duration of
illness prior to admission to hospital (days), fever (defined
as a prolonged temperature >37.5 °C), abdominal discom-
fort, vomiting, watery diarrhea (defined as three or more
loose bowel movements during a 24-h period), bloody or
mucoid diarrhea (defined as >3 loose stools with obvious
blood or mucus), estimated number of episodes of diar-
rhea before attending hospital, and if there was any known
pretreatment with antimicrobials.
Sources of Shigellae
Isolates recovered from all 12 sites of Antimicrobial
Resistance surveillance network in Nepal during 2003–
2015 were reported to NPHL and were included in the
study.
Fig. 2 Region wise reported cases of total Shigella isolates (n = 232)
Table 1 Annual distribution of different serotypes of Shigella (2003–2015)
Year S. dysentriae N (%) S. flexneri N (%) S. sonnei N (%) S. boydii N (%) Unidentified Shigella spp. Total
2003 13 (52 %) 7 (28 %) 2 (8 %) 3 (12 %) – 25
2004 28 (63.7 %) 12 (27.3 %) 2 (4.5 %) 2 (4.5 %) – 44
2005 10 (19.6 %) 31 (60.8 %) 6 (11.8 %) 4 (7.8 %) – 51
2006 6 (26.1 %) 14 (60.9 %) 2 (8.7 %) 1 (4.3 %) – 23
2007 10 (27 %) 22 (59.5 %) 3 (8.1 %) 2 (5.4 %) – 37
2008 2 (11.8 %) 8 (47.2 %) 1 (5.8 %) 1 (5.8 %) 5 (29.4 %) 17
2009 8 (40 %) 5 (25 %) 1 (5 %) 1 (5 %) 5 (25 %) 20
2010 5 (50 %) 4 (40 %) – – 1 (10 %) 10
2011 2 (18.2 %) 5 (45.4 %) 2 (18.2 %) – 2 (18.2 %) 11
2012 2 (18.2 %) 6 (54.5 %) 3 (27.3 %) – – 11
2013 5 (16.1 %) 21 (67.7 %) 3 (9.7 %) – 2 (6.5 %) 31
2014 1 (4 %) 12 (48 %) 5 (20 %) 1 (4 %) 6 (24 %) 25
2015 3 (11.1 %) 19 (70.4 %) 4 (14.8 %) – 1 (3.7 %) 27
Total 95 (28.6 %) 166 (50 %) 34 (10.2 %) 15 (4.5 %) 22 (6.6 %) 332
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Laboratory methods
Stool specimens received at respective laboratories were
cultured for enteric pathogens, including Shigella spp.
by standard methods [17]. Sample was streaked onto
MacConkey agar and a selective medium (either deoxy-
cholate citrate agar or xylose lysine deoxycholate agar or
Salmonella-Shigella agar) (all media by HiMedia, India) by
the quadrant isolation technique [18]. The plates were
incubated at 37 °C for 24 h. Isolates were identified by
Gram’s staining, colony characteristics, and biochemical
tests.
After identification of isolates, they were subcultured
onto nutrient agar slants in screw capped tube, incubated
overnight and then transported to NPHL in a cold box. All
reported isolates of Shigella were re-confirmed by serotyp-
ing using commercially available antisera from Denka
Seiken, Japan, and were preserved in tryptic soy broth
with 20 % glycerol at −75 °C for further use. Antibiotic
susceptibility test was performed for all the identified
Shigella isolates by Standard Kirby Bauer’s disc diffu-
sion technique. The antibiotics used for analysis were
ampicillin (Amp-10 mcg), cotrimoxazole (Sxt-25 mcg),
nalidixic acid (NA-30 mcg), ciprofloxacin (Cip-5 mcg),
mecillinam (Mec), and ceftriaxone (CRO-5 mcg).
Statistical methods
Data obtained were analyzed using SPSS software for
windows version 18. Data on variables like shigella sero-
types, age group, and sex were calculated as percentages
and compared using chi-square test. P < 0.05 was consid-
ered to be statistically significant. Duplicate samples
were counted as one during data entry.
Results
A total of 332 Shigella isolates were reported in a period
of 2003–2015 from 12 participating laboratories of Anti-
microbial Resistance surveillance network in Nepal. The
Fig. 3 Seasonal distribution of total reported cases (n = 232)
Fig. 4 Percentage of laboratory-confirmed Shigella infection reported to NPHL, by age group and sex (n = 196 with age and sex information reported)
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Table 2 Antimicrobial susceptibility profile of various species of Shigella (2003–2015)
N (%) resistance to
Year Species Number tested Ampicillin Ciprofloxacin Nalidixic acid Cotrimoxazole Mecillinam Ceftriaxone
2003 S. dysentriae 13 11 (85) 8 (62) 10 (77) 9 (69) 5 (38) 0
S. flexneri 7 7 (100) 0 0 6 (86) 2/6 (33)a 0
S. boydii 3 2 (66) 0 1 (33) 2 (66) 2 (66) 0
S. sonnei 2 1 (50) 0 2 (100) 2 (100) 1 (50) 0
2004 S. dysentriae 28 25 (89) 13 (46) 14 (50) 18 (64) 20/27 (74)a 0
S. flexneri 12 9 (75) 6 (50) 6 (50) 8 (67) 4 (33) 0
S. boydii 2 1 (50) 0 0 1 (50) 0 0
S. sonnei 2 0 0 2 (100) 2 (100) 0 0
2005 S.dysentriae 10 8 (80) 6/9 (66)a 7 (70) 8 (80) 2/8 (25)a 0
S. flexneri 31 18/30 (60)a 0 17/28 (59)a 21 (68) 13 (42) 0
S. boydii 6 4 (66) 0 3 (50) 0 4 (66) 0
S. sonnei 4 1 (25) 0 2 (50) 2 (50) 0 0
2006 S. dysentriae 6 4/5 (80)a 0 4/5 (80)a 2/5 (40)a 4 (66) 0
S. flexneri 14 8/13 (62)a 3/12 (25)a 4/10 (40)a 7/12 (58)a 14 (100) 0
S. boydii 2 0 0 0 0 0 0
S. sonnei 1 S R R S S S
2007 S. dysentriae 10 5/6 (83)a 4 (40) 2 (20) 2 (20) 10 (100) 0
S. flexneri 22 17/21 (81)a 12/21 (57)a 21 (95) 19/21 (90)a 22 (100) 2/20 (10)a
S. boydii 3 3 (100) 0 0 0 3 (100) 0
S. sonnei 2 0 0 0 0 2 (100) 0
2008 S. dysentriae 2 0 2 (100) 2 (100) 0 2 (100) 0
S. flexneri 8 8 (100) 3/5 (60)a 8 (100) 4/5 (80)a 8 (100) 0
S. sonnei 2 2 (100) 0 2 (100) 0 2 (100) 0
Shigella spp. 5 3 (60) 1/4 (25)a 2/4 (50)a 3/4 (75)a 5 (100) 1/3 (33)a
2009 S. dysentriae 8 8 (100) 2 (25) 7 (88) 7 (88) 8 (100) 0
S. flexneri 6 4/5 (80)a 6 (100) 4/5 (80)a 6 (100) 6 (100) 2 (33)
S. sonnei 1 R S R S R S
Shigella spp. 5 3 (60) 3 (60) 4 (80) 4 (80) 5 (100) 2 (40)
2010 S. dysentriae 5 5 (100) 1 (20) 5 (100) 5 (100) – 0
S. flexneri 4 4 (100) 1 (25) 4 (100) 4 (100) – 0
Shigella spp. 1 R S R R – S
2011 S. dysentriae 2 2 (100) 1 (50) 1 (50) 2 (100) – 0
S. flexneri 5 3 (60) 0 0 3/4 (75)a – 0
S. sonnei 2 1 (50) 0 2 (100) 0 – 0
Shigella spp. 2 2 (100) 0 2 (100) 2 (100) – 0
2012 S. dysentriae 4 4 (100) 0 3 (75) 3 (75) – 0
S. flexneri 7 7 (100) 4/6 (66)a 3/4 (75)a 4/6 (67)a – 2/6 (33)a
S. sonnei 3 0 0 1 (33) 3 (100) – 0
2013 S. dysentriae 5 5 (100) 0 4 (80) 3 (60) – 0
S. flexneri 19 15/16 (93)a 12/17 (71)a 16/18 (89)a 14 (74) – 5/18 (27)a
S. sonnei 3 3 (100) 2 (66) 2 (66) 2 (66) – 0
Shigella spp. 3 3 (100) 0 3 (100) 3 (100) – 0
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highest number was reported in 2005. Peak isolation was
seen in post monsoon season, i.e., September (Fig. 2).
Shigella dysenteriae was the prevalent species in Nepal
in the years 2003–2004 but since 2005, S. flexneri replaced
it and became the most prevalent species. A marked in-
crease in the number of S. sonnei (N = 6) was noticed in
the year 2005 which is highest reported till date. In con-
trast, no isolate of S. boydii was reported since 2009 till
2014 where one isolate was reported. Since 2008, few
cases of unidentified Shigella isolates were also reported
(Table 1).
Region wise distribution of reported isolates showed
that 18 isolates of Shigella were reported from one la-
boratory in the eastern development region, 188 isolates
were reported from seven participating laboratories in
the central development region, and 126 were reported
from four participating laboratories in the western devel-
opment region (Fig. 3).
Of the total, 24.5 % of cases were demonstrated in
children below 10 years followed by 21–30 years age
group (22.9 %) and 11–20 years age group (18.5 %). Sig-
nificant difference was not noted (p = 0.059) in age wise
distribution of cases over the years. Shigella infection
was reported higher among male in age groups below
30 years and 71–80 years but higher cases were reported
in females of age groups 31–70 years and 80+ years
(Fig. 4).
The antimicrobial susceptibility profile of Shigella iso-
lates in the years 2003–2015 is shown in Table 2. Different
serotypes of Shigella exhibited various resistance patterns.
S. dysentriae showed varying resistance to ampicillin (80–
100 %), co-trimoxazole (20–100 %), and nalidixic acid
(20–100 %). Likewise, S. flexneri also exhibited varying
resistance to ampicillin (80–100 %), co-trimoxazole
(58–100 %), and nalidixic acid (0–100 %). Until 2003,
only S. dysentriae strains exhibited resistance to cipro-
floxacin; however, 50 % of the S. flexneri isolates were
resistant to ciprofloxacin by 2004. By 2012, S. dysen-
triae strains were found susceptible to ciprofloxacin in
contrast to S. flexneri, which exhibited highest
resistance. Among S. sonnei and S. boydii serotypes,
resistance to ampicillin, cotrimoxazole, and nalidixic
acid kept varying. Only three S. sonnei isolates were
found resistant to ciprofloxacin while no
ciprofloxacin-resistant S. boydii was reported. All the
serotypes of Shigella were 100 % resistant to mecillinam
since 2007; so by 2010, mecillinam was no longer included
in antimicrobial testing of Shigella. Among the serotypes, re-
sistance to ceftriaxone was first reported in S. flexneri (10–
33 %) followed by non-typable Shigella spp. with around
40 % resistance; 22.2% of the total isolates tested were resist-
ant to all three antimicrobials. Figure 5 demonstrates the cu-
mulative antibiogram of various species of Shigella.
The prevalence of multidrug-resistant (resistance to
two or more classes of antibiotics) Shigella isolates is
demonstrated in Fig. 5. The prevalence of MDR increased
significantly in 2010 as compared to 2003. On the basis of
their pattern of antimicrobial resistance to the six antibi-
otics used in the study, the reported Shigellae were
grouped into seven phenotypes (Table 3). Among the Shi-
gella serotypes, high prevalence of MDR was observed in
S. dysentriae isolates occupying 52 % of the total isolates.
Discussion
Shigellosis still accounts for a significant proportion of
mortality and morbidity, especially in developing countries
[19]. The present study, covering 13 years surveillance
(2003–2015), demonstrates the changing serotype and trend
of antimicrobial resistance of Shigella isolates in Nepal.
An analysis of serotypes revealed that S. dysenteriae was
the prevalent species in Nepal in the years 1999–2004 but
a change in serotype in Shigella species was noticed dur-
ing 2005. The changing patterns in the distribution of
Shigella serogroups and serotypes have been reported
from time to time [20–23]. In our study, S. flexneri
remained the most prevalent serotype in Nepal since
2005 which is in accordance with many recent studies in
Nepal and other developing countries [9, 15, 17, 24–27]
but dissimilar to some other studies [28–30]. It has been
hypothesized that these changes may be due to varying
Table 2 Antimicrobial susceptibility profile of various species of Shigella (2003–2015) (Continued)
2014 S. dysentriae 1 S R S S – S
S. flexneri 12 7/11 (64)a 8 (66) 11 (92) 7 (58) – 0
S. sonnei 5 3 (60) 5 (100) 5 (100) 5 (100) – 0
S. boydii 1 S R R R – S
Shigella spp. 6 6 (100) 1/5 (20)a 3/4 (75)a 3 (50) – 0
2015 S. dysentriae 3 0 0 3 (100) 2 (75) – 0
S. flexneri 19 16/18 (88)a 9 (47) 15 (79) 17 (89) – 3 (16)
S. sonnei 4 3 (75) 4 (100) 4 (100) 4 (100) – 0
Shigella spp. 1 R S R R – S
aThe number in which antibiotics were incorporated, if less than the total number of isolates
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behavourial and environmental factors such as reduction
of overall malnutrition, use of safe drinking water instead
from tubewells or pipes, and improved sanitary facilities
for defecation [31].
In our study, like in other studies, the seasonal tendency
of shigellosis was summer-monsoon [9, 15]. This may be
because during this period, there is a climatic variation
due to which the sources of drinking water gets rapidly
contaminated. Males were more commonly infected as
compared to females as in other studies made by Khan et
al. and Taneja [15, 32]. This male preponderance may be
due to greater chances of exposure to male population
who go out of the house much frequently than females for
eating food from restaurants and street vendors. The sus-
ceptible age group in our study, like in other studies, was
below 10 years [12, 15, 25]. In our study, very few cases
were reported from children below 5 years. This may be
because the laboratories in the surveillance network are
limited; many cases may be referred to private institutions
which are not included in the surveillance network. Be-
sides that, other factors like incomplete information on
age (16 % missing) available from participating laborator-
ies, inclusion of only one children’s hospital in the surveil-
lance and low Shigella isolation rate may have contributed
to under reporting of true number of victims.
Treatment of shigellosis depends on appropriate anti-
microbial therapy. A variety of antibiotics are effective
for treatment of shigellosis, although options are becom-
ing limited due to globally emerging drug resistance.
The present study also shows high resistance among all
Shigella species to the first line low cost drugs commonly
used in the treatment of shigellosis like Ampicillin, Cotri-
moxazole and Nalidixic acid. Considering resistance pat-
tern in different groups, S. flexneri and S. dysentriae, the
two most common serotypes revealed similar pattern in
resistance with slightly higher range in S. flexneri. How-
ever, the difference was not statistically significant. Similar
studies conducted by Khan et al. reveals that S. flexneri ex-
hibited increased resistance to ampicillin and nalidixic
acid as compared to S. dysentriae whereas high resistance
was observed against ciprofloxacin and cotrimoxazole in
S. flexneri as compared to S. dysentriae [15]. This finding
however does not agree with some previous studies
done by Wilson et al. and Kansakar et al. [9, 12] in
Nepal which demonstrates high resistance in S. dysentriae.
Among remaining serotypes, untypable Shigella spp. ex-
hibited high resistance to all antimicrobials except cipro-
floxacin as compared to S. sonnei and S. boydii. S. boydii
exhibited least resistance to all antimicrobials tested. This
finding is also in accordance to studies made by Khan
Table 3 Multidrug-resistant phenotypes of Shigella
MDR phenotype Number (%) of isolates exhibiting resistance
S. dysentriae S. flexneri S. boydii S. sonnei Shigella spp.
Amp/Cip or NA/Mec 1 (1.9 %) 3 (5.2 %) 2 (50 %) – –
Amp/Mec/Ts 5 (9.4 %) 3 (5.2 %) – – –
Mec/Cip or NA/Ts 2 (3.8 %) 3 (5.2 %) – 1 (10 %) –
Amp/NA or Cip/Ts 25 (47.2 %) 36 (62.1 %) 1 (25 %) 9 (90 %) 3 (50 %)
Amp/NA or Cip/Ts/Mec 20 (37.7 %) 5 (8.6 %) – – 3 (50 %)
Amp/NA or Cip/Ts/Mec/CRO – 1 (1.7 %) 1 (25 %) – –
Amp/NA or Cip/Ts/CRO – 7 (11.9 %) – – –
Total number MDR (%) 53 (55.8 %) 58 (34.9 %) 4 (26.6 %) 10 (29.4 %) 6 (27.3 %)
Fig. 5 Year wise distribution of MDR isolates (in number and percentage)
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et al. [15] but contradictory to findings by Kansakar et al.
[9] which reveals S. sonnei as the most susceptible sero-
type. Emerging resistance to ceftriaxone in S. dysentriae,
S. flexneri, and Shigella spp. is noted which raises concern
for the use of third-generation cephalosporins as last ther-
apy of treatment.
This difference in antimicrobial resistance among vari-
ous serotypes may be attributed to change in time period
of the studies. Studies conducted during 2004/2005
showed contradictory result in terms of prevalent sero-
type and resistance profile among serotypes as compared
to that of 2013/2014 which seems obvious.
MDR (resistance to three or more than three antibi-
otics) was found in 46.1 % of total isolates, and the most
common MDR profile was ampicillin, nalidixic acid, and
cotrimoxazole. This finding is very low as compared to
90.2 % reported by Reema et al. However, the MDR pro-
file is similar [33].
Limitations
Data represented from our 12 surveillance sites may not
be representative of the sick population at large in the
community. Lack of total number of reported cases and
inadequate data management systems also limited the
results of our study.
Conclusions
With increasing resistance to first-line agents along with
ciprofloxacin, only ceftriaxone remains the drug of choice;
however, increasing MDR along with resistance to third-
generation cephalosporins as last resort creates an alarm-
ing situation warranting proper usage of antimicrobial
agents and its continuous monitoring.
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